Full-Life Technologies will inaugurate a unique nuclear medicine site in Gembloux, Belgium, on November 24, to produce radioisotopes specifically targeting cancer cells, as part of an initiative to strengthen the Belgian ecosystem in nuclear medicine. (translated)









